Analyst Price Target is $85.00
▲ +36.79% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Morphic in the last 3 months. The average price target is $85.00, with a high forecast of $103.00 and a low forecast of $50.00. The average price target represents a 36.79% upside from the last price of $62.14.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Morphic. This Buy consensus rating has held steady for over two years.
Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.